MedinCell S.A. (MEDCL.PA)
EUR 16.8
(5.53%)
EUR 16.8
(5.53%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -20.97 Million EUR | 14.31% |
| 2022 | -27.83 Million EUR | 1.1% |
| 2021 | -28.14 Million EUR | -47.9% |
| 2020 | -19.03 Million EUR | 15.29% |
| 2019 | -22.46 Million EUR | -44.8% |
| 2018 | -15.51 Million EUR | -110.3% |
| 2017 | -7.37 Million EUR | -105.57% |
| 2016 | -3.58 Million EUR | -952.49% |
| 2015 | 421 Thousand EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 FY | -23.85 Million EUR | 14.31% |
| 2023 Q2 | -10.16 Million EUR | 0.0% |
| 2023 Q4 | -11.99 Million EUR | 0.0% |
| 2022 Q2 | -13.35 Million EUR | 0.0% |
| 2022 Q4 | -14.47 Million EUR | 0.0% |
| 2022 FY | -27.83 Million EUR | 1.1% |
| 2021 Q2 | -13.76 Million EUR | 0.0% |
| 2021 Q4 | -14.37 Million EUR | 0.0% |
| 2021 FY | -28.14 Million EUR | -47.9% |
| 2020 FY | -19.03 Million EUR | 15.29% |
| 2020 Q4 | -8.94 Million EUR | 0.0% |
| 2020 Q2 | -10.1 Million EUR | 0.0% |
| 2019 Q4 | -12.31 Million EUR | 0.0% |
| 2019 FY | -22.46 Million EUR | -44.8% |
| 2019 Q2 | -10.05 Million EUR | 0.0% |
| 2018 Q4 | -8.89 Million EUR | -100.0% |
| 2018 Q3 | -4.44 Million EUR | 32.82% |
| 2018 Q1 | -3.3 Million EUR | -15.76% |
| 2018 Q2 | -6.61 Million EUR | -100.0% |
| 2018 FY | -15.51 Million EUR | -110.3% |
| 2017 Q2 | -4.1 Million EUR | -100.0% |
| 2017 Q4 | -2.85 Million EUR | -100.0% |
| 2017 FY | -7.37 Million EUR | -105.57% |
| 2017 Q3 | -1.42 Million EUR | 65.22% |
| 2017 Q1 | -2.05 Million EUR | 0.0% |
| 2016 FY | -3.58 Million EUR | -952.49% |
| 2015 FY | 421 Thousand EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.41 Million EUR | -514.801% |
| ABIVAX Société Anonyme | -127.37 Million EUR | 83.531% |
| Adocia SA | -17.62 Million EUR | -19.039% |
| Aelis Farma SA | -6.46 Million EUR | -224.671% |
| Biophytis S.A. | -14.33 Million EUR | -46.355% |
| Advicenne S.A. | -6.45 Million EUR | -224.872% |
| genOway Société anonyme | 2.06 Million EUR | 1115.69% |
| IntegraGen SA | -183.77 Thousand EUR | -11314.812% |
| Medesis Pharma S.A. | -4.22 Million EUR | -395.987% |
| Neovacs S.A. | -6.9 Million EUR | -203.682% |
| NFL Biosciences SA | -4.43 Million EUR | -373.477% |
| Plant Advanced Technologies SA | -778.23 Thousand EUR | -2595.451% |
| Quantum Genomics Société Anonyme | -3.13 Million EUR | -568.642% |
| Sensorion SA | -22.31 Million EUR | 5.978% |
| Theranexus Société Anonyme | -7.64 Million EUR | -174.436% |
| TME Pharma N.V. | -5.62 Million EUR | -272.991% |
| Valbiotis SA | -7.16 Million EUR | -192.975% |
| TheraVet SA | -2.17 Million EUR | -864.411% |
| Valerio Therapeutics Société anonyme | -20.28 Million EUR | -3.396% |
| argenx SE | -417.15 Million EUR | 94.971% |
| BioSenic S.A. | -7.04 Million EUR | -197.969% |
| Celyad Oncology SA | -8.45 Million EUR | -148.043% |
| DBV Technologies S.A. | -85.24 Million EUR | 75.392% |
| Galapagos NV | -88.26 Million EUR | 76.234% |
| Genfit S.A. | -26.58 Million EUR | 21.08% |
| GeNeuro SA | -14.35 Million EUR | -46.107% |
| Hyloris Pharmaceuticals SA | -15.99 Million EUR | -31.164% |
| Innate Pharma S.A. | -12.66 Million EUR | -65.577% |
| Inventiva S.A. | -102.7 Million EUR | 79.576% |
| MaaT Pharma SA | -19.94 Million EUR | -5.185% |
| Nanobiotix S.A. | -26.77 Million EUR | 21.666% |
| Onward Medical N.V. | -35.46 Million EUR | 40.848% |
| Oryzon Genomics S.A. | -4.54 Million EUR | -361.115% |
| OSE Immunotherapeutics SA | -22.98 Million EUR | 8.74% |
| Oxurion NV | -12.11 Million EUR | -73.22% |
| Pharming Group N.V. | -4.87 Million EUR | -329.897% |
| Poxel S.A. | -28.76 Million EUR | 27.072% |
| GenSight Biologics S.A. | -29.69 Million EUR | 29.361% |
| Transgene SA | -30.01 Million EUR | 30.105% |
| Financière de Tubize SA | -2.14 Million EUR | -878.417% |
| UCB SA | 604 Million EUR | 103.473% |
| Valneva SE | -82.08 Million EUR | 74.445% |
| Vivoryon Therapeutics N.V. | -28.83 Million EUR | 27.257% |